Article Text

Download PDFPDF

Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with type 2 diabetes mellitus, is atorvastatin better than placebo for primary prevention of major cardiovascular disease (CVD) events?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★★☆ Cardiology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial (Collaborative Atorvastatin Diabetes Study [CARDS]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (clinicians, patients, pharmacists, data collectors, outcome assessors, monitoring committee, and data analysts).*

Embedded ImageFollow-up period:

median 3.9 years.

Embedded ImageSetting:

132 clinical centres in the UK and Ireland.

Embedded ImagePatients:

2838 patients 40–75 years of age (mean age 62 y, 68% men) with type 2 diabetes mellitus (met 1985 World Health Organization criteria) who had ⩾1 of the following: a history of hypertension, retinopathy, microalbuminuria or macroalbuminuria, or a current smoking habit. Exclusion …

View Full Text

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd